Rule 11 is the classification rule in Annex VIII of the MDR for medical device software. It classifies software according to the significance of the information it provides for diagnostic or therapeutic decisions and according to the consequences of an incorrect decision. As a result, the same technical platform may fall into different risk classes depending on its intended purpose.<\/p>\n
Software that provides information on the basis of which diagnostic or therapeutic decisions are made is classified as Class IIa by default. If a decision may cause death or an irreversible deterioration of the state of health, the rule leads to Class III. If the decision may cause serious deterioration of health or a surgical intervention, the classification is Class IIb.<\/p>\n
For the assessment, it is not sufficient that an application displays data. What is decisive is whether the information provided is actually intended to be used for a diagnostic or therapeutic decision. The intended purpose must therefore describe specifically what information the software generates, who uses it, what decision it influences, and what consequences incorrect, delayed, or missing information may have. General product names or marketing statements do not replace this analysis.<\/p>\n
Software for monitoring physiological processes is classified as Class IIa by default under Rule 11. If it monitors vital physiological parameters where the nature of variations can cause an immediate danger to the patient, Class IIb is provided. The classification therefore requires a medical assessment of the monitored parameter, the expected rate of change, and the user’s ability to respond.<\/p>\n
All other software falls into Class I. This catch-all provision is not intended for software that prepares decisions or monitors physiological processes whose risk significance has been described imprecisely. Before applying Rule 11, it must also be clarified whether the software independently meets the definition of medical device software at all. Administrative, lifestyle, or general communication functions do not become medical device software solely by virtue of their proximity to healthcare.<\/p>\n
Rule 11 does not depend on energy or substance exchange. Rules 9, 10, and 12 of Annex VIII, by contrast, assess certain active devices and take into account their delivery or exchange of energy and substances. For software, the relevant risk pathway is the information and its influence on care, not the question of whether the underlying device uses electrical energy.<\/p>\n
This is particularly important for software combined with hardware. A sensor, a monitor, and an analysis application may interact without the classification of the software being simply derived from the class of the hardware. The functions must be described separately. If the software delivers its own information for decisions, its role is assessed under Rule 11; a purely control function may require a different assessment.<\/p>\n
Classification is also relevant in the event of changes. If an algorithm is modified so that it no longer merely informs but outputs a therapy prioritization, the risk significance of the function may change. Manufacturers must therefore re-examine their intended purpose and the consequences of a malfunction against Rule 11 for significant software versions. An update is not regulatorily insignificant simply because it is technically delivered via the same user interface.<\/p>\n
In a clinical investigation of medical device software, Rule 11 influences the regulatory strategy, the scope of clinical evidence, and the involvement of a Notified Body. Studies must examine the claimed information performance in the intended use situation. For decision-support applications, it is therefore important which reference method is used, how misclassifications are recorded, and what consequence an incorrect output may have for the diagnostic or therapeutic decision.<\/p>\n
Full-service CROs such as Mediconomics support the translation of the software intended purpose into clinical endpoints, the planning of validation studies, data management for software versions, and the preparation of clinical evaluation documentation. They can structure the documentation so that algorithm version, data source, user role, and observed performance limits remain assigned to the investigated configuration.<\/p>\n
The MDCG divides Rule 11 into the sub-areas of decision information, monitoring of physiological processes, and other software. This sequence helps to describe the function precisely first, rather than arguing backwards from a supposedly obvious class.<\/p>\n
When does software become Class III under Rule 11?<\/strong><\/p>\n When its information is intended for diagnostic or therapeutic decisions and those decisions may cause death or an irreversible deterioration of the state of health.<\/p>\n Is every monitoring app Class IIa?<\/strong><\/p>\n Not every app is classified as medical device software at all. For qualified software for monitoring physiological processes, Class IIa is the starting point; for vital parameters with immediate danger, Class IIb.<\/p>\n Why is the intended purpose so important for Rule 11?<\/strong><\/p>\n It determines whether and how the information is to be used for decisions or monitoring. Only from this can the harm potential of erroneous information be assessed.<\/p>\n Rule 11 is the classification rule in Annex VIII of the MDR for medical device software. It classifies software according to the significance of the information it provides for diagnostic or therapeutic decisions and according to the consequences of an incorrect decision. As a result, the same technical platform may fall into different risk classes […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[24],"class_list":["post-8032","glossary","type-glossary","status-publish","hentry","glossary-cat-medizinprodukte-ivd"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8032\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8032"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n